FUJIFILM Holdings America Corporation's Commitment during the Novel Coronavirus (COVID-19) Pandemic

To aid in prevention, we stand ready to support the manufacture of vaccines with world-class biologics production facilities and technical expertise. Of note, FUJIFILM Diosynth Biotechnologies has been selected to manufacture Novavax' COVID-19 vaccine candidate at its North Carolina facilities. In addition, it has reserved manufacturing capacity at its Flexible Biomanufacturing Facility in Texas to expand production of a COVID-19 vaccine candidate as part of Operation Warp Speed. FUJIFILM Diosynth Biotechnologies is also leveraging its manufacturing and technical expertise to team up with the COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies.

In the field of diagnosis, our efforts include the provision of a gene-testing research tool which lessens the time required for polymerase chain reaction (PCR) testing*. Our point-of-care imaging equipment such as ultrasound and mobile X-ray systems are playing a vital role in the clinical care of patients with COVID-19. With a heightened awareness of respiratory symptoms amid the COVID-19 outbreak, there is an increased focus on pulmonary diagnostic exams for which Fujifilm offers a broad range of endoscopes for pulmonary indications.

Our work in the treatment field includes clinical trials in Japan and the U.S. to evaluate the safety and efficacy of our influenza antiviral drug Avigan® Tablet for patients with COVID-19. Additionally. FUJIFILM Group life science companies are providing critical raw materials necessary for the development of potential COVID-19 vaccines and therapies.

As this is a rapidly evolving situation, we have adjusted our business practices in order to safeguard the health and safety or our workers, customers and the community, and to comply with various recently ordered state and local orders. We are following governmental orders in the locations where we operate and we have frequently communicated supply chain and distribution updates to our partners.

We are also taking proactive measures to ensure the health and safety of our staff and customers. As such, we have temporarily closed the Wonder Photo Shop in New York City and the camera repair drop-off and pick-up in Edison, New Jersey. During this time, we are still committed to providing exceptional service to our customers. For support, customers are still welcome to contact us.

As a company, we are doing our part to enhance society, as well as taking precautions for our workforce. To respond to emerging events tied to COVID-19, Fujifilm has directed specific procedures in order to maintain a safe workforce. Until further notice, we have enacted a work-from-home policy for all non-essential personnel, social distancing and split shifts for essential workers on-site, extensive cleaning procedures at our sites, encouraging workers to follow good hygiene practices based on the CDC guidelines, as well as restricting travel, meetings, events and visitors, to comply with social distancing requirements.

Overall, FUJIFILM North America Corporation is involved in a number of manufacturing businesses that are supporting essential and critical operations at this time including graphic plates, ink and other supplies for newspapers and media services; packaging and supplies for Healthcare organizations; and supplies for industry X-ray film and imaging plates for essential infrastructure. Fujifilm is committed to supporting these businesses during this critical time.

In addition, several of our sister Fujifilm companies in the United States are engaged in healthcare and life science products and services; this includes diagnostic imaging equipment, which is critical to the care process of COVID-19 patients; the manufacture and production of cell culture media, which are raw materials for therapies, vaccines and diagnostics; as well as providing contract development and manufacturing services to various bio-pharma companies.